Core Viewpoint - Mereo BioPharma Group plc is facing a class action lawsuit due to alleged securities fraud, with a lead plaintiff deadline set for April 6, 2026, for investors who purchased American Depositary Shares (ADS) during the specified class period [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Mereo provided misleading information regarding the expected results of its Phase 3 Orbit and COSMIC studies for setrusumab in treating Osteogenesis Imperfecta (OI) [5]. - Defendants allegedly made positive statements about setrusumab's potential to reduce annualized fracture rates while concealing adverse facts about the studies, which did not meet their primary endpoints [6]. Group 2: Investor Actions - Investors who purchased Mereo ADSs during the class period may be entitled to compensation without upfront costs through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][7].

Core Viewpoint - Rosen Law Firm is reminding purchasers of American Depositary Shares (ADS) of Mereo BioPharma Group plc about the upcoming lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company regarding its clinical studies [1][3]. Group 1: Class Action Details - Investors who purchased Mereo ADSs between June 5, 2023, and December 26, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 6, 2026 [3]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions of dollars for investors [4]. Group 3: Case Background - The lawsuit alleges that Mereo BioPharma provided investors with misleading information regarding the expected results of its Phase 3 Orbit and COSMIC studies for setrusumab in Osteogenesis Imperfecta (OI) [5]. - The defendants reportedly made positive statements about setrusumab's potential to reduce annualized fracture rates while concealing adverse facts about the studies, which did not meet their primary endpoints [6].

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc on behalf of investors who purchased its American Depositary Shares during the specified class period, alleging misleading information regarding clinical study results [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague PC, representing investors who bought Mereo ADS from June 5, 2023, to December 26, 2025 [1][2]. - Investors have until April 6, 2026, to seek appointment as lead plaintiff representative of the class [2]. Group 2: Allegations Against Mereo - The complaint claims that Mereo misled investors by raising expectations about the ORBIT and COSMIC studies, which tested setrusumab for Osteogenesis Imperfecta, while concealing that neither study significantly reduced clinical fracture rates compared to control groups [3]. - Following the disclosure of the study results, Mereo's ADS price fell dramatically from $2.31 on December 26, 2025, to $0.29 on December 29, 2025, resulting in a loss of over 87.7% of its value in one day [3]. Group 3: Company Background - Mereo BioPharma Group plc is a biopharmaceutical company based in London, focusing on treatments for rare diseases [2].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Ultragenyx Pharmaceutical Inc due to alleged violations of federal securities laws related to misleading statements about the efficacy of its drug setrusumab in treating Osteogenesis Imperfecta [2][4]. Group 1: Allegations and Legal Actions - The complaint alleges that Ultragenyx and its executives misrepresented their knowledge regarding the effects of setrusumab, creating a false impression of reliability while downplaying risks associated with the Phase III Orbit study [4]. - The company reportedly failed to disclose that the optimism surrounding the Phase III Orbit study's results was unfounded, as it relied on Phase II results without a placebo control group, which could have led to misleading conclusions about the drug's effectiveness [4]. - Following the announcement on July 9, 2025, that the Phase III Orbit study did not achieve statistical significance, Ultragenyx's stock price fell by over 25% [5]. Group 2: Study Results and Stock Impact - On December 29, 2025, Ultragenyx disclosed that both the Phase III Orbit and Cosmic studies did not meet primary endpoints for reducing annualized clinical fracture rates compared to placebo or bisphosphonates, attributing the failure to a low fracture rate in the placebo group [6]. - This announcement resulted in a further decline of over 42% in Ultragenyx's stock price [7]. Group 3: Class Action Details - The deadline for investors to seek the role of lead plaintiff in the federal securities class action against Ultragenyx is April 6, 2026 [2]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [8].

Core Viewpoint - Rosen Law Firm is reminding purchasers of American Depositary Shares (ADS) of Mereo BioPharma Group plc about the upcoming lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company during the Class Period from June 5, 2023, to December 26, 2025 [1]. Group 1: Class Action Details - Investors who purchased Mereo ADSs during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 6, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. - The firm has achieved notable settlements, including the largest securities class action settlement against a Chinese company and has consistently ranked highly in securities class action settlements since 2013 [4]. Group 3: Case Background - The lawsuit alleges that Mereo BioPharma provided investors with misleading information regarding the expected results of their Phase 3 studies for setrusumab in treating Osteogenesis Imperfecta [5]. - Defendants reportedly made positive statements about the drug's potential while concealing adverse facts, leading to inflated prices for Mereo's ADSs [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Mereo BioPharma Group plc due to alleged violations of federal securities laws related to misleading statements about clinical trial results [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses in Mereo BioPharma to contact them to discuss their legal options [1]. - There is a deadline of April 6, 2026, for investors to seek the role of lead plaintiff in a federal securities class action against Mereo BioPharma [2]. - The complaint alleges that Mereo BioPharma and its executives made false statements and failed to disclose the true state of their Phase 3 clinical programs [4]. Group 2: Clinical Trial Results - Mereo BioPharma announced that two Phase 3 studies of setrusumab failed to meet their primary endpoints of reducing annualized clinical fracture rates compared to placebo and bisphosphonates [5]. - Despite the primary endpoint misses, the trials showed statistically significant improvements in bone mineral density on secondary endpoints, and no new safety concerns were identified [5]. Group 3: Market Reaction - Following the announcement of the failed trials, Mereo's stock price plummeted by $2.02 per share, a decrease of 87.64%, closing at $0.28 per share on December 29, 2025 [6].

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. on behalf of investors who purchased its common stock during the specified Class Period, highlighting concerns over misleading statements regarding clinical trial outcomes [1][3]. Group 1: Lawsuit Details - The lawsuit pertains to investors who bought Ultragenyx common stock from August 3, 2023, to December 26, 2025 [1][2]. - Investors have until April 6, 2026, to seek appointment as lead plaintiff representative of the class [2]. Group 2: Clinical Trials and Impact - Throughout the Class Period, Ultragenyx made positive statements about the ORBIT and COSMIC Phase 3 programs, which were clinical trials for setrusumab as a treatment for Osteogenesis Imperfecta [3]. - On December 29, 2025, Ultragenyx revealed that neither clinical trial achieved its primary endpoint, leading to a significant drop in share price of over 42%, from $34.19 to $19.72 [4].

Core Viewpoint - Rosen Law Firm is reminding purchasers of American Depositary Shares (ADS) of Mereo BioPharma Group plc about the upcoming lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company during the Class Period from June 5, 2023, to December 26, 2025 [1]. Group 1: Class Action Details - Investors who purchased Mereo ADSs during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 6, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action litigation [4]. Group 3: Case Background - The lawsuit claims that Mereo BioPharma provided investors with misleading information regarding the expected results of their Phase 3 studies for setrusumab in treating Osteogenesis Imperfecta [5]. - Defendants allegedly made positive statements about the drug's efficacy while concealing adverse facts about the studies, which did not meet their primary endpoints [6].

Core Viewpoint - The Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding the efficacy of their drug setrusumab during clinical trials [1][3]. Company Overview - Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing treatments for rare and ultra-rare genetic diseases [2]. Allegations of the Lawsuit - The lawsuit claims that Ultragenyx misrepresented the reliability of information regarding the effects of setrusumab on Osteogenesis Imperfecta (OI) patients and downplayed the risks associated with the Phase III Orbit study [3]. - It is alleged that Ultragenyx's optimism regarding the Phase III Orbit study's results was unfounded, as the company did not adequately disclose the risks of relying on Phase II results that lacked a placebo control group [3]. Impact of Study Results - On July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study did not achieve statistical significance for its second interim analysis, leading to a stock price drop of over 25% [4]. - Following a December 29, 2025 announcement that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, Ultragenyx's stock price fell by more than 42% [5]. Legal Process for Lead Plaintiff - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Ultragenyx common stock during the class period to seek appointment as lead plaintiff in the lawsuit, representing the interests of all class members [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone, marking its fourth 1 ranking in the past five years [7].

Core Viewpoint - Rosen Law Firm is reminding purchasers of American Depositary Shares (ADS) of Mereo BioPharma Group plc about the upcoming lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company regarding its clinical studies [1][2]. Group 1: Class Action Details - Investors who purchased Mereo ADSs between June 5, 2023, and December 26, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 6, 2026 [3]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms issuing notices may lack the necessary experience and resources [4]. - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions of dollars for investors [4]. Group 3: Case Background - The lawsuit alleges that Mereo BioPharma provided misleading information regarding the expected results of its Phase 3 Orbit and COSMIC studies for setrusumab in Osteogenesis Imperfecta (OI) [5]. - Defendants reportedly made positive statements about setrusumab's potential while concealing adverse facts about the studies, which did not meet their primary endpoints, leading to artificially inflated stock prices [6].